SPEAK TO A SCIENTIST

ImmunoCAP

For IgE-Mediated Hyperreactivity Analysis

The ImmunoCAP platform is used to determine drug induced IgE-mediated immune responses, supporting the diagnosis of allergic reaction against biologicals. BioAgilytix offers ImmunoCAP at our European laboratory in Hamburg, Germany to deliver accurate and reproducible analysis results with increased efficiency for shortened lead times.

 

Learn More About the ImmunoCAP Platform:

Still have questions?

BioAgilytix’s experts are here to help. Let’s schedule a conversation to review your questions and requirements with one of our scientists.
Speak to a scientist

HOW THE IMMUNOCAP PLATFORM WORKS

The technology used in the ImmunoCAP platform enables a high binding capacity per mg cellulose in combination with an optimal amount of cellulose in each solid phase. This ensures binding of all relevant antibodies, regardless of antibody affinity, still giving low non-specific binding. The ImmunoCAP solid phase consists of a cellulose derivative enclosed in a capsule. The hydrophilic, highly branched polymer provides an ideal microenvironment for allergens, binding them irreversibly while maintaining their native structure.

The test is designed as a sandwich immunoassay. Biotinylated drug, bound to streptavdine-coated solid phase, reacts with the drug-specific IgE in the patient serum sample. After washing, enzyme-labeled antibodies against IgE are added to form a complex. After incubation, unbound enzyme-labeled anti-IgE is washed away and the bound complex is then incubated with a developing agent. After stopping the reaction, the fluorescence of the eluate is measured. The fluorescence is directly proportional to the concentration of IgE in the serum sample.

Discuss Your Project

Why BioAgilytix for Small and Large Molecule Bioanalysis?

Our passion for the science of small and large molecule bioanalysis drives our ability to deliver premium, tailored services for biomarker, immunogenicity, pharmacokinetics (PK), and cell-based assays.

SEE HOW

IDEAL IMMUNOCAP APPLICATIONS: FOR IGE-MEDIATED HYPERREACTIVITY ANALYSIS

ImmunoCAP offers a very sensitive IgE detection in the low ng- or pg range with high precision. It is used to determine site infusion reaction that is mediated in IgE, and enables IgE antibody development to be detected at an early stage, indicating sensitization—even before clinical symptoms have developed.

As such, BioAgilytix is able to use ImmunoCAP in immunogenicity studies evaluating an IgE-mediated type I hypersensitivity reaction against biologicals with excellent consistency and reliability.

let’s discuss your project

KEY IMMUNOCAP BENEFITS: AUTOMATED PROCESSING AND REPRODUCIBLE RESULTS

The key advantages of ImmunoCAP are its ability to enable high productivity, high sensitivity, and high drug tolerance – and because of its automated processing, the platform is able to provide accurate, standardized, and reproducible test results.

Designed as sandwich assays, the solid phase of ImmunoCAP ensures binding of all, but only relevant antibodies. This is achieved through an extreme binding capacity in combination with an optimal amount of cellulose in each ImmunoCAP vial.

We use ImmunoCAP assays to deliver accurate and reproducible analysis results with increased efficiency and shortened lead times, achieved with the platform’s high-throughput automation capabilities.

Top Benefits of the ImmunoCAP Platform:

  • High Sensitivity
  • Automated Processing
  • High Accuracy
  • Standardized, Reproducible Results

Platform In Action:

Managing unwanted immunogenicity of therapeutic proteins

Learn why the European Immunogenicity Platform (EIP) believes that a multidisciplinary approach is warranted to better understand and minimize drug immunogenicity.

Download our paper

BIOAGILYTIX’S IMMUNOCAP PLATFORM EXPERTISE

Our veteran scientific team has proven their ability to efficiently, consistently perform assays using ImmunoCAP, and to interpret the data derived for accurate, timely results. We have vast collective experience leveraging this platform to determine drug induced IgE-mediated immune responses.

Learn how we can support your unique assay requirements with ImmunoCAP today.

Speak To A Scientist





    I consent to receive communications (which may include, phone, email, social, and re-targeting ads) from BioAgilytix. I understand I may proactively manage my preferences or opt-out of communications with BioAgilytix at any time using the unsubscribe link provided in all of BioAgilytix’s email communications and can learn more by reading the privacy policy.

    Services

    See how our premier bioanalytical services support all phases of biomarker, immunogenicity, PK, and cell-based assay studies.
    EXPLORE OUR SERVICES

    Case Studies

    Learn why we’re a trusted partner to 22 of the top 25 global pharma and biotech companies.
    READ OUR CASE STUDIES
    CONTACT US
    ↑
    USA HQ

    2300 Englert Dr

    Durham, NC, 27713

    919-381-6097

    Fax 919-381-6099

    San Diego Laboratory

    9050 Camino Santa Fe

    San Diego, CA 92121

    858-652-4600

    Fax 858-652-4699

    Brisbane Laboratory

    37 Kent St, Woolloongabba

    Queensland, 4102, Australia

    Subscribe to Our Newsletter
    USA HQ

    2300 Englert Dr

    Durham, NC, 27713

    919-381-6097

    Fax 919-381-6099

    San Diego Laboratory

    9050 Camino Santa Fe

    San Diego, CA 92121

    858-652-4600

    Fax 858-652-4699

    Brisbane Laboratory

    37 Kent St,Woolloongabba

    Queensland, 4102, Australia

    Boston Laboratory

    1320 Soldiers Field Road

    Boston, MA, 02135

    617-456-0700

    Fax 617-456-0701

    Boston Laboratory

    1320 Soldiers Field Road

    Boston, MA, 02135

    617-456-0700

    Fax 617-456-0701

    European HQ

    Lademannbogen 10

    22339 Hamburg Germany

    +49 405267790

    Melbourne Laboratory

    85 Commercial Road, Melbourne

    Victoria, 3004, Australia

    +61 3 9282 2184